» Articles » PMID: 28989853

Xenotransplantation: Where Are We with Potential Kidney Recipients? Recent Progress and Potential Future Clinical Trials

Overview
Date 2017 Oct 10
PMID 28989853
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Inter-species transplantation, xenotransplantation, is becoming a realistic strategy to solve the organ shortage crisis. Here we focus on seminal publications that have driven research in xenotransplantation, as well as recently published literature and future endeavors.

Recent Findings: Advances in gene editing technology have allowed for the efficient production of multi-transgenic porcine donors leading improved xenograft survival in baboons, up to 2-years following heterotopic heart xenotransplantation and from weeks to several months following life-supporting kidney xenotransplanation. As technology evolves, additional challenges have arisen, including the development of proteinuria, early graft loss associated with porcine CMV, disparities in organ growth between donors and recipients as well as high-dose continuous immunosuppression requirements. To address these issues, our laboratory developed a tolerance-inducing protocol which has allowed for >6 months survival of a life-supporting kidney with further approaches currently underway to address the challenges mentioned above.

Summary: Our recent findings, reviewed in this article, led us to develop methods to overcome obstacles, which, in conjunction with the work of others, are promising for future clinical applications of xenotransplantation.

Citing Articles

Developments in kidney xenotransplantation.

Xu H, He X Front Immunol. 2024; 14:1242478.

PMID: 38274798 PMC: 10808336. DOI: 10.3389/fimmu.2023.1242478.


Transplanting organs from pigs to humans.

Sykes M, Sachs D Sci Immunol. 2019; 4(41).

PMID: 31676497 PMC: 7293579. DOI: 10.1126/sciimmunol.aau6298.


Justification of specific genetic modifications in pigs for clinical organ xenotransplantation.

Cooper D, Hara H, Iwase H, Yamamoto T, Li Q, Ezzelarab M Xenotransplantation. 2019; 26(4):e12516.

PMID: 30989742 PMC: 10154075. DOI: 10.1111/xen.12516.


IXA Honorary Member Lecture, 2017: The long and winding road to tolerance.

Sykes M Xenotransplantation. 2018; 25(3):e12419.

PMID: 29913040 PMC: 6011233. DOI: 10.1111/xen.12419.

References
1.
Cooper D, Good A, Koren E, Oriol R, Malcolm A, Ippolito R . Identification of alpha-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transpl Immunol. 1993; 1(3):198-205. DOI: 10.1016/0966-3274(93)90047-c. View

2.
Sevigny J, Robson S, Waelkens E, Csizmadia E, Smith R, Lemmens R . Identification and characterization of a novel hepatic canalicular ATP diphosphohydrolase. J Biol Chem. 2000; 275(8):5640-7. DOI: 10.1074/jbc.275.8.5640. View

3.
Mohiuddin M, Singh A, Corcoran P, Thomas III M, Clark T, Lewis B . Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft. Nat Commun. 2016; 7:11138. PMC: 4822024. DOI: 10.1038/ncomms11138. View

4.
Cowan P . The use of CRISPR/Cas associated technologies for cell transplant applications. Curr Opin Organ Transplant. 2016; 21(5):461-6. DOI: 10.1097/MOT.0000000000000347. View

5.
Goldwich A, Burkard M, Olke M, Daniel C, Amann K, Hugo C . Podocytes are nonhematopoietic professional antigen-presenting cells. J Am Soc Nephrol. 2013; 24(6):906-16. PMC: 3665387. DOI: 10.1681/ASN.2012020133. View